Dachaigh › Lymphoma Burkitt › Arkansas
Sgrùdaidhean clionaigeach Lymphoma Burkitt ann an Arkansas
Tha 5 sgrùdaidhean airson Lymphoma Burkitt a’ lorg phàirtichean aig làraichean ann an Arkansas.
Bailtean ann an Arkansas
Teacsa sgrùdaidh oifigeil (Beurla)
A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)
- Arkansas Children's Hospital, Little Rock
A’ fastadhÌre 2
366 Days – 46 Years · Gach gnè · Air ùrachadh 2 Dàmh 2026 · NCT06124157Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia
- Arkansas Children's Hospital, Little Rock
A’ fastadhÌre 2
365 Days · Gach gnè · Air ùrachadh 25 Sult 2026 · NCT06317662A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)
- Arkansas Children's Hospital, Little Rock
A’ fastadhÌre 2
Aoisean 1 gu 30 · Gach gnè · Air ùrachadh 1 Sult 2026 · NCT04546399Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy
- Arkansas Children's Hospital, Little Rock
A’ fastadhÌre 3
365 Days – 25 Years · Gach gnè · Air ùrachadh 25 Lùna 2026 · NCT03959085A Multi-site Study to Evaluate the Persistence of Protective Immunity to Routine Childhood Vaccinations in Participants With B-ALL/Ly Who Have Received Blinatumomab
- Arkansas Children's, Little Rock
- Arkansas Children's Northwest, Springdale
A’ fastadhSgrùdadh amharc
Aoisean 1 gu 23 · Gach gnè · Air ùrachadh 25 Gearr 2026 · NCT07422337Bho ClinicalTrials.gov, dàta air a thogail 5 Dàmh 2026. Bidh gach sgrùdadh a’ suidheachadh a chuidi fhèin; bidh an sgioba sgrùdaidh a’ co-dhùnadh cò as urrainn pàirt a ghabhail.